Bright Minds Biosciences (NASDAQ:DRUG) Sees Strong Trading Volume – Time to Buy?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares saw unusually-high trading volume on Wednesday . Approximately 355,033 shares traded hands during trading, an increase of 87% from the previous session’s volume of 189,967 shares.The stock last traded at $77.08 and had previously closed at $76.78.

Key Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Bright Minds Biosciences and reiterated a $145 price target, implying significant upside versus the current share price. Benzinga
• Positive Sentiment: The analyst slightly raised some near- and medium-term EPS estimates, including Q1 2027, Q3 2027, Q4 2027 and FY2026, which may have helped sentiment around the stock. Street Insider
• Neutral Sentiment: The updated forecasts still call for substantial losses over the next several years, so the revisions are supportive but not a sign of near-term profitability.
• Negative Sentiment: Some estimates were cut, including Q2 2027, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029, which tempers the bullish analyst tone.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DRUG. HC Wainwright reissued a “buy” rating and issued a $145.00 price target on shares of Bright Minds Biosciences in a research note on Monday. BTIG Research reissued a “buy” rating and issued a $147.00 price target on shares of Bright Minds Biosciences in a research note on Monday, March 30th. Jefferies Financial Group began coverage on Bright Minds Biosciences in a research note on Monday, April 13th. They issued a “buy” rating and a $145.00 price target on the stock. Robert W. Baird set a $126.00 price target on Bright Minds Biosciences in a research note on Friday, February 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $220.00 price target (up from $190.00) on shares of Bright Minds Biosciences in a report on Wednesday, May 20th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $143.83.

Bright Minds Biosciences Trading Up 1.3%

The firm has a market capitalization of $757.05 million, a price-to-earnings ratio of -31.88 and a beta of -5.53. The firm has a 50 day moving average price of $82.27 and a two-hundred day moving average price of $79.96.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its earnings results on Wednesday, May 20th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.06. As a group, research analysts forecast that Bright Minds Biosciences Inc. will post -4.99 earnings per share for the current year.

Insider Buying and Selling

In other Bright Minds Biosciences news, major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $89.50, for a total value of $9,785,124.50. Following the transaction, the insider owned 950,000 shares in the company, valued at $85,025,000. The trade was a 10.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 42.66% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bright Minds Biosciences

A number of institutional investors have recently made changes to their positions in DRUG. Millennium Management LLC raised its position in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock valued at $6,946,000 after purchasing an additional 152,178 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Bright Minds Biosciences in the 1st quarter valued at about $802,000. Geode Capital Management LLC acquired a new stake in shares of Bright Minds Biosciences in the 2nd quarter valued at about $1,502,000. JPMorgan Chase & Co. raised its stake in shares of Bright Minds Biosciences by 624.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after purchasing an additional 1,873 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Bright Minds Biosciences in the 2nd quarter valued at about $107,000. 40.52% of the stock is owned by institutional investors and hedge funds.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.